InMed Pharmaceuticals (IMLFF) versus The Competition Head-To-Head Contrast

InMed Pharmaceuticals (OTCMKTS:IMLFF – Get Rating) is one of 471 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare InMed Pharmaceuticals to similar businesses based on the strength of its profitability, valuation, earnings, risk, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of current ratings for InMed Pharmaceuticals and its peers, as reported by MarketBeat.

Get InMed Pharmaceuticals alerts:

As a group, “Biotechnology” companies have a potential upside of 130.39%. Given InMed Pharmaceuticals’ peers higher probable upside, analysts clearly believe InMed Pharmaceuticals has less favorable growth aspects than its peers.

Institutional and Insider Ownership

31.9% of shares of all “Biotechnology” companies are held by institutional investors. 23.6% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares InMed Pharmaceuticals and its peers revenue, earnings per share (EPS) and valuation.

InMed Pharmaceuticals’ peers have higher revenue and earnings than InMed Pharmaceuticals. InMed Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares InMed Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

InMed Pharmaceuticals Company Profile

(Get Rating)

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, it works on IND-enabling pharmacology and preclinical toxicology studies. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.